Genetic markers predict primary non-response and durable response to anti-TNF biologic therapies in Crohn’s disease

BACKGROUND: One-fifth of patients with Crohn’s Disease (CD) are primary non-responders (PNR) to anti-tumor necrosis factor (anti-TNF) therapy, and an estimated 10–15% will fail therapy annually. Little is known about the genetics of response to anti-TNF therapy. The aim of our study was to identify...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Am J Gastroenterol
Main Authors: Barber, Grant E, Yajnik, Vijay, Khalili, Hamed, Giallourakis, Cosmas, Garber, John, Xavier, Ramnik, Ananthakrishnan, Ashwin N
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5143156/
https://ncbi.nlm.nih.gov/pubmed/27596696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ajg.2016.408
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki